Immune-mediated epilepsy with GAD65 antibodies

Area of Science:

• Neurology
• Immunology
• Neuroscience

Background:

• Anti-glutamic acid decarboxylase 65 (GAD65) antibodies are detected in various seizure disorders, including limbic encephalitis and chronic epilepsy.
• High antibody titers and intrathecal synthesis are diagnostic indicators but show weak correlation with disease severity or treatment response.

Purpose of the Study:

• To review recent advances in GAD65-epilepsy, focusing on diagnosis, epidemiology, pathophysiology, clinical features, and treatment.
• To improve recognition and therapeutic strategies for GAD65-antibody-associated epilepsy.

Main Methods:

• Literature review of recent advances in GAD65-epilepsy.
• Analysis of diagnostic criteria, epidemiological data, and pathophysiological mechanisms.
• Evaluation of clinical presentations and treatment outcomes.

Main Results:

• GAD65 antibodies are implicated in both acute and chronic epilepsy syndromes.
• The pathogenic role of anti-GAD65 antibodies versus their function as markers for T-cell mediated autoimmune disorders remains debated.
• Patients with GAD65-epilepsy often exhibit poor prognosis, frequent relapses, and potential progression to broader central nervous system inflammation.

Conclusions:

• GAD65-epilepsy poses significant therapeutic challenges with limited efficacy and poor prognosis.
• Further understanding of GAD65-epilepsy is crucial for developing targeted therapies and improving patient outcomes.
• This review aims to enhance clinical recognition and management of this autoimmune neurological condition.